A historic slowdown in U.S. healthcare spending in recent years may be drawing to a close.
An industry report published Tuesday and healthcare experts point to a steady rise in medical care being sought by consumers seeing specialists, getting more prescriptions filled and visiting the hospital. Other factors such as millions of newly insured Americans seeking treatment for the first time and higher prices from healthcare consolidation could also help drive up costs.
Experts aren't predicting an immediate return to double-digit increases in medical spending. But the emerging trend underscores how difficult it will be for policymakers, employers and health plans to control healthcare costs going forward.
"2013 was a rebound year for healthcare," said Murray Aitken, executive director of the IMS Institute for Healthcare Informatics, an industry research firm that released Tuesday's report. "We saw healthcare usage overall up for the first time in three years. We think that is reflective of a strong economy, more patients with insurance and also some pent-up demand for services that may have been delayed or deferred since the economic downturn."
David Gruber, director of healthcare research at Alvarez & Marsal, said he's expecting a similar trend of higher demand coupled with consolidation among hospitals and large physician groups pushing up prices. He said the demand for services is being driven by an influx of
"At some point you can't defer anymore," Gruber said. Health spending "isn't going up by double digits, but it could spike to 6% or 7%."
There are other forces at play that could serve as an effective counterweight and bear watching. The growing use of narrow provider networks by employers and health insurance companies and a shift away from conventional fee-for-service reimbursement for medical providers can be potent cost-containment tools, Gruber said.
On Monday, the
David Axene, a fellow at the Society of Actuaries, estimates that rates for individual consumers under the health law may rise, on average, 6% to 8.5% next year. He cautions that rates will vary across the country, and some health insurers such as industry giant WellPoint Inc. have already warned about double-digit rate hikes in some markets.
"Many exchange health plans got better discounts than anticipated from providers, but there is really a strong pushback now from hospitals and physicians who are concerned about having enough money to cover their costs," said Axene, an actuary in Murrieta. "I hope we can stay south of double digits, but there's no guarantee we will."
From 2009 to 2012, U.S. healthcare spending grew annually at less than 4%, according to federal data. That's been the lowest rate of growth in half a century, and has sparked considerable debate about the underlying reasons.
Many health economists and industry officials have attributed the slowdown primarily to lingering effects of the Great Recession, when millions of Americans cut back on medical care. But the Obama administration and other experts have pointed to fundamental changes in healthcare reimbursement and the delivery of care spurred by the Affordable Care Act.
Patent protections expiring on major drugs and cheaper generic substitutes flooding the market helped drive that previous decrease. Aitken said patent expirations had less impact last year and there was greater use of healthcare in general.
IMS Health also found that the number of physician office visits, hospitalizations and prescriptions filled all rose last year.
At the doctor's office, visits to primary care physicians fell less than 1%, but trips to specialists jumped 5%. The number of hospital visits also grew last year, primarily among commercially insured patients who received outpatient treatment.
Any upswing in medical costs could further squeeze workers. Their health insurance premiums keep taking a bigger bite of their paychecks, as employers shift more healthcare costs to employees.
There was some good news for consumers. The IMS report found that 57% of all retail prescriptions filled last year cost consumers $5 or less. But patients often bear a growing share of the cost for high-priced specialty medications for cancer, rheumatoid